You just read:

Azevan Pharmaceuticals Completes Enrollment in Phase 2 Clinical Study of SRX246 in Intermittent Explosive Disorder

News provided by

Azevan Pharmaceuticals, Inc.

09 May, 2016, 10:39 ET